Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NUWE Nuwellis > Key Indicators
NUWE Nuwellis
0.155
+0.001+0.65%
Post Mkt Price
0.157
+0.002+1.42%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-13.51% 170.049 18.56% 182.5489 10.69% 200.0621 34.24% 213.129
Receivable Turnover(T)
-7.99% 7.2347 -21.10% 6.1317 -9.70% 8.4802 9.60% 9.5722
Inventory Turnover(T)
-1.42% 1.2327 -14.27% 1.2196 -23.12% 1.0565 -16.92% 1.1828
Fixed Assets Turnover(T)
-17.82% 4.6898 -26.27% 4.3962 -22.86% 4.3855 -17.47% 4.2529
Total Asset Rate(T)
3.75% 0.2987 -24.47% 0.2957 -25.02% 0.2658 -45.93% 0.3141
ROIC
-4.44% -75.144% 4.65% -81.945% 7.41% -70.569% 45.88% -89.779%
ROE
-6.11% -77.201% 3.53% -84.411% 6.58% -72.494% 46.24% -92.999%
ROA
-2.13% -64.658% 1.97% -71.370% 6.59% -63.255% 36.97% -77.943%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- 9.54% -253.603%
ROA 5 Year Average
-- -- -- -- -- -- 2.41% -166.803%
Average 5 Years ROIC
-- -- -- -- -- -- 9.76% -239.962%
Profitability Ratios TTM
Gross Margin
-3.43% 55.034% 1.85% 54.742% 7.67% 58.355% 3.99% 56.697%
Operating Margin
7.60% -216.263% -8.58% -239.704% -3.24% -236.146% -7.72% -246.509%
Net Margin
1.56% -216.454% -29.79% -241.381% -24.59% -238.012% -16.58% -248.113%
EBITDA Margin
7.41% -2.1109% -8.82% -2.3397% -3.22% -2.3026% -7.40% -2.4035%
R & D Expense Ratio
-7.41% 54.450% 37.67% 66.410% 33.51% 64.790% 27.51% 62.850%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
5,148.96% 5.779% 3,041.15% 4.954% 2,612.08% 4.288% 467.71% 3.792%
Total Assets to Common Equity
15.67% 131.543% 9.23% 124.536% 8.73% 120.237% -4.41% 117.227%
Debt to Asset Ratio
1,218.99% 7.392% 608.47% 6.159% 459.14% 5.232% 118.35% 4.536%
Current Ratio
-47.20% 4.5528 -26.48% 5.7589 -30.67% 7.0445 64.49% 8.505
Quick Ratio
-53.14% 3.6425 -31.02% 4.8158 -34.46% 5.9702 76.33% 7.5461
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -40.63% 16.590%
Revenue CAGR(5Y)
-- -- -- -- -- -- -73.16% 43.782%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
CEO: Mr. Nestor Jaramillo, Jr
Market: NASDAQ
Listing Date: 02/16/2012
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist